NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
6 trialsNCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
NCT03847649 2025-06-11
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT03406650 2025-05-04
SAKK 06/17
Swiss Cancer Institute
Phase 2 Completed
NCT05000710 2024-12-05
CORAL-Lung
Sheba Medical Center
Phase 2 Active not recruiting
NCT03094286 2024-06-24
Durvalumab in HIV-1 Patients With Solid Tumors
Spanish Lung Cancer Group
Phase 2 Completed